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Ischemia and inflammation may be pathophysiological mechanisms of complex regional pain syndrome (CRPS). Ketamine has
proposed anti-inflammatory effects and has been used for treating CRPS. This study aimed to evaluate anti-inflammatory and
analgesic effects of ketamine after ischaemia-reperfusion injury in a chronic postischaemia pain (CPIP) model of CRPS-I. Using
this model, ischemia was induced in the hindlimbs of male Sprague-Dawley rats. Ketamine, methylprednisolone, or saline was
administered immediately after reperfusion. Physical effects, (oedema, temperature, and mechanical and cold allodynia) in the
bilateral hindpaws, were assessed from 48 hours after reperfusion. Fewer (56%) rats in the ketamine group developed CPIP at
the 48th hour after reperfusion (nonsignificant). Ketamine treated rats showed a significantly lower temperature in the ischaemic
hindpaw compared to saline (𝑃 < 0.01) and methylprednisolone (𝑃 < 0.05) groups. Mechanical and cold allodynia were
significantly lower in the ischaemic side in the ketamine group (𝑃 < 0.05). Proinflammatory cytokines TNF-𝛼 and IL-2 were
significantly lower at the 48th hour after reperfusion in ketamine andmethylprednisolone groups, compared to saline (all𝑃 < 0.05).
In conclusion, immediate administration of ketamine after an ischaemia-reperfusion injury can alleviate pain and inflammation in
the CPIP model and has potential to treat postischaemic pain.
1. Introduction
Complex regional pain syndrome (CRPS) is a chronic neu-
ropathic pain disorder. Its key features in humans include
spontaneous pain, hyperalgesia, allodynia, and abnormal
vasomotor and sudomotor activities [1]. The incidence is
about 26.2 per 100,000 persons and it is more prevalent
among females than males [2]. CRPS is divided into two
types: CRPS-II involves nerve injury while CRPS-I does
not. The pathophysiological mechanisms of CRPS remain
poorly understood but the clinical features suggest that the
pathogenesis involves inflammation, ischaemia, nerve regen-
eration, and abnormal cross talk between affected nerves and
blood vessels that are characterized by complicated cellular
and molecular changes [3–5]. The blister fluid of CRPS
patients has high levels of interleukin- (IL-) 6 and tumour
necrosis factor-alpha (TNF-𝛼) [6]. Interleukin- (IL-) 2 and
TNF-𝛼 are also elevated systemically in patients with CRPS-I
[7].Thus, drugs modulating the cytokine system have started
to be used for CRPS pain management in clinical trials [8].
Ketamine, an N-methyl-D-aspartate (NMDA) receptor
antagonist and dissociative anaesthetic, has been shown to
produce analgesia by inhibiting both normal and pathologic
pain pathways [9]. Activated by glutamate, the NMDA recep-
tor is believed to play an important role in the development of
central sensitization, which can induce chronic pain, includ-
ingCRPS. NMDA receptor antagonismmay attenuate central
sensitization and further reduce the symptoms of CRPS.
In addition, ketamine has an anti-inflammatory effect [10],
which may partially contribute to its analgesic properties. It
Hindawi Publishing Corporation
Oxidative Medicine and Cellular Longevity
Volume 2015, Article ID 380403, 9 pages
http://dx.doi.org/10.1155/2015/380403
2 Oxidative Medicine and Cellular Longevity
has been used to treat CRPS clinically and shows promise
in this area [11]. However, to date, there has been no study
conducted to evaluate its anti-inflammatory analgesic effects
in pain conditions. In this study, we also compared the anti-
inflammatory effects of ketaminewithmethylprednisolone (a
glucocorticoid anti-inflammatory agent), which served as a
positive control, to investigate whether ketamine had addi-
tional therapeutic effects compared to methylprednisolone
on a postischaemic pain model.
We hypothesized that if administered early after
ischaemia-reperfusion injury, ketamine would modify the
postischaemic responses, including pain and inflammation,
in the CPIP animal model established by Coderre and
colleagues [12]. The model has been shown to mimic
CRPS-I reliably by 3-hour inductions of ischaemia
and reperfusion [12], presenting hyperaemia, plasma
extravasation, mechanical and cold allodynia, and the
induction of TNF-𝛼, IL-2, IL-6, and nuclear factor kappa B
(NF𝜅B) [13].
2. Materials and Methods
All procedures were carried out according to the US National
Institutes of Health Guide for the Care and Use of Laboratory
Animals and were approved by the Committee on the Use of
Live Animals in Teaching and Research at the University of
Hong Kong. The license to conduct experiments was issued
by the Department of Health, the Government of the Hong
Kong Special Administrative Region.
2.1. Animal Preparation. There were three treatment groups
in this study: a ketamine treatment group (group KE), a
methylprednisolone (corticosteroid) treatment group (group
MP), and a 0.9% saline treatment group (group NS). Ten
270∼300 g adult male SD rats (Charles River Laboratories,
USA) were used for each group based on our preliminary
study (unpublished). The animals were housed individually
in isolated cages with food and water available ad libitum,
on a 12 : 12 h light : dark cycle in the laboratory animal unit
at the University of Hong Kong. The room temperature was
maintained at 23∘C and humidity ranged between 25% and
45%.
2.2. CPIP Criteria. Successful development of CPIP relies
on the existence of mechanical allodynia, which meets the
criteria of a 30% decrease in the mechanical threshold of
an ischaemic limb (ipsilateral side) at the forty-eighth hour
after reperfusion [12]. Those fulfilling the criteria would be
regarded as having successfully developed CPIP.The propor-
tion of rats meeting the criteria for successful development of
CPIP was calculated. Since effects on the modification of the
postischaemic responses (anti-inflammatory and analgesic
effects) of early ketamine administration were assessed, all of
the rats in this study were recruited to evaluate physical signs,
pain behaviour, and serum proinflammatory cytokine levels.
2.3. CPIP Model and Drug Administration. The rats were ini-
tially anaesthetised with intraperitoneal (i.p.) pentobarbital
40mg/kg, followed by 13mg per hour for the first hour and
6.5mg for the second hour. Three doses were given in total.
To induce ischaemia, a tourniquet (Nitrile 70 Durometer O-
ring) with 7/32-inch internal diameter was placed around
the rat’s left hindlimb (ipsilateral) near the ankle joint and
proximal to the medial malleolus. The O-rings were selected
to produce a tight-fit that produced ischaemia similar to
that produced by a blood pressure of 350mmHg and were
left on the limb for 3 hours. Blood flow to the limb was
confirmed with laser Doppler [12]. Briefly, a laser Doppler
probe (DP1T-V2; Moor Instruments, Axminster, UK) and a
fibre were loosely taped to the plantar surface of the ipsilateral
paw. Blood flow was recorded with a DRT4 monitor (Moor
Instruments, Axminster, UK). At the third hour, the O-
ring was cut and reperfusion occurred. The termination of
sodium pentobarbital anaesthesia was timed so that the rats
recovered fully within 30–60 minutes following reperfusion.
The study drugs ketamine (100mg/kg), methylprednisolone
(30mg/kg), and 0.9% saline in a bolus of 0.5mL were given
intraperitoneally, immediately after the removal of the O-
ring tourniquet. Dose of ketamine was chosen according to
a previous study on intestinal ischaemia-reperfusion injury
[14]. Methylprednisolone was used as a positive control and
the dose was determined according to a study of methylpred-
nisolone on ischaemia-reperfusion injury in rat livers [15].
2.4. Physical Signs and Behaviour Assessment. The rats were
taken to the laboratory platform for one hour per day
for a total of two days prior to the experiment and 30
minutes before behaviour assessment on the experiment day
to become accustomed to the laboratory environment. The
investigator assessing the physical signs and pain behaviour
of the rats was blinded to the studymedications administered.
2.5. Hindpaw Temperature. Coderre’s CPIP animal model
showed an increase in skin temperature in the ischaemic
hindpaw lasting for two hours after reperfusion [12]. A ther-
mocouple wire was used tomeasure the baseline temperature
of both hindpaws before ischaemia and from the fifthminute
to the seventh day after the reperfusion. Three sites were
tested over the dorsum of the hindpaw.These were the spaces
between the first and secondmetatarsals (medial), the second
and the third metatarsals (central), and the fourth and fifth
metatarsals (lateral) in medial, central, and lateral sequence.
The three measurements were averaged to obtain a mean
temperature for each side.
2.6. Hindpaw Thickness. The thickness of the hindpaw was
measured as an indication of hindpaw volume and oedema
after induction of CPIP, as it has been reported that the
hindpaw volume can be presented as hindpaw thickness [16].
In this experiment, a manual calliper was used to measure
the ventral thickness of both hindpaws (maximum dorsal) at
baseline before ischaemia and from the fifth minute to the
seventh day after reperfusion.The calliper was lightly applied
to the skin without tissue displacement.
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2.7. Mechanical Allodynia. The criterion for successful devel-
opment of CPIP is a 30% reduction in the mechanical allody-
nia threshold on the ipsilateral hindpaw. This was measured
by assessing the hindpaw withdrawal threshold with a von
Frey fibre of an Electrovonfrey apparatus (IITC/Life Science
Instruments). A blunt fibre with a stiffness of 65 g was
applied against the hindpaw plantar skin at approximately
the midsole, avoiding the tori pads. It was pushed until it is
slightly bent, and a hindpaw withdrawal within 6–8 seconds
of the stimulus was considered a positive response. The force
(in grams) that was needed to elicit a positive response was
then recorded and shown on the screen of the Electrovonfrey
apparatus. The withdrawal threshold was measured at 5- to
10-minute intervals, alternating between the right and left
sides until each side had been tested twice. The readings of
the ischaemic and contralateral sides were averaged to give a
mean withdrawal threshold for each side. This was measured
at baseline before ischaemia and from the sixth hour to the
seventh day after reperfusion.
2.8. Cold Allodynia. Cold allodynia was measured as a
decrease in withdrawal latency to acetone, according to
Coderre et al. [12]. The measurements started at baseline
before ischaemia and from the sixth hour to the seventh day
after reperfusion.The rats were placed in a clear plastic cylin-
der on a glass surface maintained at a constant temperature
of 23∘C. After 15minutes of acclimatization, a drop of acetone
was placed on the skin of the heel. Unlike normal rats which
usually ignore the stimulus, CPIP rats often respond to it
with an exaggerated withdrawal that we were able to time.
The hindpaw withdrawal latency was repeatedly measured
at 5–10-minute intervals, alternating between the right and
left sides until each side had been tested twice. The two
withdrawal latencies of both ischemic and contralateral sides
were averaged to give mean withdrawal latency.
2.9. Heat Threshold. Heat threshold was assessed by timing
hindpawwithdrawal latency to radiant heat using a fabricated
radiant heat device according to Vatine et al. [17]. The time
measurements started at baseline before ischemia and from
the sixth hour to the seventh day after reperfusion. Rats
were placed in a clear plastic cylinder on a glass surface
maintained at a constant temperature of 23∘C. After 15
minutes of acclimatization, a radiant light source was focused
on the heel of the ischaemic side hindpaw. The hindpaw
withdrawal latency was measured at 5–10-minute intervals,
alternating between the right and left sides, until each side
had been tested twice. The two withdrawal latencies of both
ischaemic and contralateral sides were averaged to give mean
withdrawal latency.
2.10. Serum Proinflammatory Cytokines. An increase in
proinflammatory cytokines can indicate the involvement of
the inflammatory process in CPIP. Blood was collected from
the tail vein forty-eight hours after reperfusion. After being
stored overnight at 4∘C, the blood was centrifuged at 1000×g
for 20 minutes. The supernatant was taken and allocated for
use. Serum TNF-𝛼 and IL-2 were measured by an enzyme-
linked immunosorbent assay (ELISA) and commercial assays
(R&D Systems, Inc., Minneapolis).
2.11. Statistical Analysis. A two-way repeated measures anal-
ysis of variance (ANOVA) was used to compare temperature,
hindpaw thickness, withdrawal threshold to von Frey fibre
and acetone, and heat thresholds in amanner that ensured the
data were compared on a complete study time-course basis
instead of individual time points. One-wayANOVAwas used
to test the serum inflammatory cytokines.When a significant
result was obtained, Tukey’s test was applied for post hoc
comparisons. The proportions of mortality and CPIP devel-
opment among groups were tested by Fisher’s exact test. Data
are presented asmean± S.E.M, anddifferences are considered
significant at a 𝑃 value ≤0.05.
3. Results
3.1. Mortality Rate and Proportion of Rats with Successful
Development of CPIP. One animal in the ketamine and two
in the methylprednisolone treatment groups died after the
injection of the study drug, making the residual number of
each group 𝑛 = 9 in group KE, 𝑛 = 8 in groupMP, and 𝑛 = 10
in group NS with no significant difference in the mortality
rate among the three groups.
Using the criteria of a 30% decrease in the withdrawal
threshold of the von Frey fibre (mechanical allodynia) on
the ischaemic side, the percentages of successful CPIP devel-
opment were 56% in the KE group, 75% in the MP group,
and 80% in the NS group. Although KE group had the
least development rate of CPIP, no statistically significant
difference among the three treatment groups could be found.
3.2. HindpawTemperature andThickness. Our thermography
study showed that the temperature on the ipsilateral side
hindpaws of group KE rats was lower than in the NS and
MP group rats (𝑃 < 0.01 and 𝑃 < 0.05, resp., Figure 1(a)).
Ketamine also attenuated the rise in the hindpaw temperature
on the contralateral side during the same period compared
with group NS (𝑃 < 0.05, Figure 1(b)). Although there was a
clear difference, it was only obvious up to the sixth hour after
reperfusion. We also monitored the hindpaw thickness but
no obvious difference was found between all three treatment
groups in the ipsilateral and contralateral sides (Figures 2(a)
and 2(b)).
3.3. Mechanical and Cold Allodynia. Ketamine significantly
alleviated both mechanical and cold allodynia in the ipsi-
lateral hindpaw. On the ipsilateral side, the withdrawal
threshold to the von Frey fibre in group KE was significantly
higher than that in groups NS and MP (𝑃 < 0.01 and 𝑃 <
0.05, resp., Figure 3(a)). On the contralateral sides, groups
KE and MP also showed a higher withdrawal threshold to
the von Frey fibre compared with group NS (all 𝑃 < 0.05,
Figure 3(b)). The withdrawal threshold to acetone in the
ketamine treatment group was significantly higher on the
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Figure 1: Hindpaw temperatures of KE, MP, and NS groups on the ipsilateral (a) and contralateral side (b) from baseline before ischaemia
until the first 7 days after reperfusion. The temperature in group KE was lower in the ipsilateral side, compared with MP (𝑃 < 0.05) and NS
(𝑃 < 0.01) groups. However, the difference was only obvious up to the 6th hour after reperfusion. Group KE also had decreased hindpaw
temperature on the contralateral side during the same period, compared with group NS (𝑃 < 0.05); ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01.
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Figure 2: Hindpaw thickness of KE, MP, and NS groups on the ipsilateral (a) and contralateral side (b) from baseline before ischaemia until
the first 7 days after reperfusion. There was no difference among all three treatment groups in the ipsilateral side during the 7-day study
period.
ipsilateral side compared with group NS (𝑃 < 0.05) and
group MP (all 𝑃 < 0.05), as shown in Figure 4(a). For
the contralateral sides, groups KE and MP also exhibited a
significantly higher withdrawal threshold to acetone stimuli
compared to group NS (all 𝑃 < 0.001, Figure 4(b)).
3.4. Heat Threshold. Fabricated radiant heat measurements
produced no obvious difference in withdrawal threshold
among all three treatment groups, in both the ipsilateral and
contralateral sides (Figures 5(a) and 5(b)).
3.5. Serum TNF-𝛼 and IL-2. Groups KE and MP were able
to markedly attenuate the increase in serum TNF-𝛼 levels
(all 𝑃 < 0.001, Figure 6(a)) and serum IL-2 (all 𝑃 < 0.05,
Figure 6(b)) forty-eight hours after reperfusion, compared
with group NS.
4. Discussion
The present study successfully reproduced Coderre’s CPIP
model by inducing CRPS-I-like symptoms such as hyper-
aemia and mechanical and cold allodynia in both the
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Figure 3: Mechanical allodynia of KE, MP, and NS groups on the ipsilateral (a) and contralateral side (b) from baseline before ischaemia
until the first 7 days after reperfusion. On the ipsilateral side, the withdrawal threshold of group KE was significantly higher than that of NS
(𝑃 < 0.01) and MP (𝑃 < 0.05). On the contralateral side, the withdrawal threshold was higher in both KE (𝑃 < 0.05) and MP (𝑃 < 0.05)
groups than that in group NS; ∗𝑃 < 0.05; ∗∗𝑃 < 0.01.
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Figure 4: Cold allodynia of KE,MP, andNS groups on the ipsilateral (a) and contralateral side (b) from baseline before ischaemia until 7 days
after reperfusion. On the ipsilateral side, the withdrawal threshold to acetone of group KE was significantly higher, compared with groups NS
(𝑃 < 0.05) and MP (𝑃 < 0.05). On the contralateral side, the withdrawal threshold to acetone was significantly higher in KE (𝑃 < 0.001) and
MP (𝑃 < 0.001) groups than that of NS; ∗𝑃 < 0.05; ∗∗∗𝑃 < 0.001.
ipsilateral and contralateral hindpaws of experimental SD
rats. The appearance of bilateral symptoms has also been
observed in other animal models of CRPS-I [18–21] and
this is often a feature in patients with CRPS-I [22, 23].
The underlying mechanism of this contralateral effect may
involve central sensitization caused by damage to muscle
tissue [24]. It is thought that persistent inflammation after
ischaemia-reperfusion injurymay sensitize and activate affer-
ent nociceptors in damaged tissue which may then lead to
central sensitization contributing to the mechanical and cold
allodynia observed in CPIP [12]. In this study, as medications
were given immediately after induction of ischaemia, the
treatment was essentially preventive of the acute phase of
CPIP.
Ketamine is an NMDA receptor antagonist that also
inhibits serotonin and dopamine reuptake, binds to 𝜇-opioid
receptors, and has effects on nerve growth factors and
voltage-gated Na+ and K+ channels. It has been shown to
produce analgesia by inhibiting normal and pathologic pain
pathways, as NMDA receptor antagonism may attenuate
central sensitization after tissue injury or inflammation [9,
25]. This may reduce secondary hyperalgesia and is reflected
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Figure 5: Heat thresholds of KE, MP, and NS groups on the ipsilateral (a) and contralateral side (b) from baseline before ischaemia to the
first 7 days after reperfusion. There was no obvious difference of withdrawal threshold to fabricated radiant heat among all treatment groups
in both ipsilateral and contralateral sides during the 7-day study period.
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Figure 6: Serum TNF-𝛼 (a) and IL-2 (b) levels of KE, MP, and NS groups at the 48th hour after reperfusion. Compared with the NS group,
serum TNF-𝛼was significantly reduced in both KE (𝑃 < 0.001) andMP (𝑃 < 0.01) groups. Serum IL-2 was also significantly reduced in both
KE and MP groups, compared with the NS group (all 𝑃 < 0.05); ∗𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001.
at the transcriptional level by a decrease in c-fos-oncogene
induction. Ketamine has also been found to have anti-
inflammatory effects [10], which may partially explain the
analgesic effect in pain conditions with an inflammatory
component, such as CRPS-I. It has been used for treatment
of CRPS clinically [26–28] and it has been shown that a
single infusion of intravenous ketamine improved pain relief
in patients with critical limb ischaemia [29]. However, there
has been no laboratory study conducted prior to our study
to evaluate the potential mechanisms of its action on the
development ofCRPS and its analgesic action onCPRS. In the
present study, both ketamine and methylprednisolone were
used to explore their effectiveness on CPIP-induced CRPS.
Methylprednisolone (a glucocorticoid with powerful anti-
inflammatory effects) was used as a positive control to deter-
mine whether ketamine had additional therapeutic effects
on this ischemia-reperfusion pain model beyond any anti-
inflammatory mechanism. Systemic TNF-𝛼 and IL-2 were
assessed 48 hours after reperfusion because our preliminary
data (unpublished) demonstrated that the difference in both
TNF-𝛼 and IL-2 was significant when compared with the
sham group (without ischemia-reperfusion). TNF-𝛼was also
shown to peak at this time point.
Based on the results of a previous study, glucocorti-
coid treatment appears to be associated with attenuation
of pain symptoms by inhibiting inflammation and reducing
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circulating inflammatory mediators [16]. Therefore, in this
study, the mechanical and cold allodynia in the contralateral
hindpaw were diminished by the administration of methyl-
prednisolone. However, rats receiving methylprednisolone
did not show a reduction in mechanical and cold allodynia
in the ipsilateral (ischaemic) hindpaw when compared with
the normal saline group. It seems that inflammation did
contribute to postischaemic pain but that this was most likely
to be only one of themechanisms resulting inmechanical and
cold allodynia in the ischaemic limb. Although it has been
reported that glucocorticoids can inhibit symptoms of CRPS-
II by preventing plasma extravasation [16, 29], oedema from
local plasma extravasation was not significantly different
between all three treatment groups in this study. Additional
evidence indicates that inflammation is involved in the CRPS
pathophysiologic mechanism. The pain produced by a low
pH infusion into the normal, contralateral limb was similar
to patients’ who reported CRPS-I pain on the ipsilateral side
[30]. Of the many pain-related inflammatory cytokines, only
a limited number have been reported as being associated with
neuropathic pain andCRPS.Willis proposed the involvement
of inflammation in the CRPS pathophysiologic mechanism
[31]. They demonstrated that the inflammatory mediators
TNF-𝛼 and IL-2 were elevated in patients with CRPS-I [7].
In fact, TNF-𝛼 and IL-6 were also found in the local blister
fluid of these patients [6].
In comparison with methylprednisolone, the therapeutic
efficacy of ketamine has been shown to be superior in this
study, and this finding most likely reflects its multimodal
effects [14]. We found a decrease in serum proinflammatory
cytokines TNF-𝛼 and IL-2, supporting an anti-inflammatory
effect. Not only does ketamine relieve the major pain
symptoms in most cases [32], but also it attenuates other
inflammatory symptoms, including oedema and temperature
[33]. Recently, a systematic review conducted by Dale and
colleagues concluded that the intraoperative administration
of ketamine could inhibit the early postoperative IL-6 inflam-
matory response [10]. However, pain relief was not one
of the outcomes measured in the studies included in this
review. Furthermore, in most studies ketamine was given at
the induction of anaesthesia, but its role in modifying the
ischemia-reperfusion response, including pain, has not been
evaluated [10]. In this present study, we assessed whether
the anti-inflammatory effects of ketamine could contribute to
pain relief and preconditioning the early stage of CPIP after
surgery to prevent further development of CRPS and con-
firmed the advantage of ketamine as an adjuvant analgesic.
Mechanismwise, Boettger and colleagues argued that dor-
sal root reflexes (DRR)might be linked to increased neuronal
activity in the central terminal of primary afferent fibres
and the aggravation of peripheral inflammation [34, 35].
Sensitization by inflammation leads to antidromic signalling
in primary afferent neurons in DRR. Therefore, pain is being
enhanced at one end, and neuropeptide release and inflam-
mation are being aggravated at each cycle at the other [34, 35].
In addition, NMDA receptors were demonstrated to mediate
responses of dorsal horn neurons to hindlimb ischemia in
rat. NMDA receptors on the presynaptic membrane might
act as autoreceptors for glutamate and enhance the incoming
series of action potentials [36]. Furthermore, activation of
postsynaptic NMDA receptors in the spinal cord by the
increased release of glutamate from primary afferents can
lead to central sensitization [37]. Thus, an NMDA antagonist
such as ketamine blocks these receptors and might have
significant effects in reducing the glutamate release from
these terminals and further attenuating the inflammatory
response [35].
In this study, ketamine administered soon after an
ischaemia-reperfusion injury has been demonstrated to
modify the postischaemic response with superior analgesic
effects when compared to methylprednisolone and normal
saline over the study period. Early hyperaemia followed by
long lasting mechanical and cold allodynia resembles the
two well-known phases of CRPS-I in humans [30, 38, 39].
We examined hyperaemia by measuring temperature in the
hindpaws and therewas an increase in temperature bilaterally
in the first 4 hours after reperfusion which mimicked the
sometimes brief hyperaemia seen in patients with CRPS-I.
The fact that ketamine attenuated the increase in temperature
in both hindpaws whilemethylprednisolone only affected the
ipsilateral side suggests that ketamine has a more prominent
effect on the hot oedematous stage in prevention of further
progression of the disease. Apart from the anti-inflammatory
effect, there are other mechanisms to explain these improved
outcomes. Ketamine not only blocks the NMDA receptor
[40], but also at a high dose blocks other receptors such as
opioid and muscarinic cholinergic receptors [40]. It inhibits
NMDA receptor-mediated central sensitization by blocking
NMDA receptors, thereby reducing the mean opening time
of the channel. It also decreases the frequency of channel
opening by an allostericmechanism [40]. Blockage ofNMDA
receptor-mediated sensitization results in attenuation of
symptoms and signs, such as mechanical and cold allodynia.
It is this action on the central nervous system that alleviates
mechanical and cold allodynia, not only in the ipsilateral
hindpaw but also in the contralateral hindpaw.
5. Conclusions
In conclusion, our study demonstrates that early treatment
with ketamine can modify postischaemic responses resulting
in less mechanical and cold allodynia and lower serum levels
of proinflammatory cytokines including TNF-𝛼 and IL-2 in a
CPIPmodel using SD rats. Althoughmethylprednisolone can
also reduce these cytokines, the analgesic efficacy was lower
than that provided by ketamine. Early administration of
ketamine can potentially be an effective approach in prevent-
ing further progression of pain conditions with an ischaemic
and inflammatory pathogenesis, including CRPS. Clinical
studies exploring the anti-inflammatory and analgesic effects
of anaesthetic doses of ketamine after ischaemia-reperfusion
injury are warranted.
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